For men with metastatic prostate cancer who are willing to accept the adverse impact on over- all survival and gynaecomastia in the hope of retaining sexual function, anti-androgen mono- therapy with bicalutamide (150 mg) 14 is appropriate. Healthcare professionals should begin androgen withdrawal and stop bicalutamide treatment in men with metastatic prostate cancer who are taking bicalutamide monotherapy and who do not maintain satisfactory sexual function. Intermittent androgen withdrawal may be offered to men with metastatic prostate cancer pro- viding they are informed that there is no long-term evidence of its effectiveness. .
